Forget GLP-1s—GLP-3s show promise in phase 3 weight loss and diabetes trial

Phase 3 objective proceedings results (TRANSCEND-T2D-1) published successful The Lancet study that retatrutide, an investigational once-weekly injection for diabetes management, tin importantly amended humor sweetener levels and pb to important value nonaccomplishment successful radical with Type 2 diabetes. The survey included adults with Type 2 diabetes who were not taking diabetes medicines and whose humor sweetener was not adequately controlled with fare and workout alone.